About Novacea
Novacea is a company based in Richmond (United States) founded in 2001 was acquired by Transcept Pharmaceuticals in September 2008. Novacea has raised $35 million across 1 funding round from investors including Apax Partners, Transcept Pharmaceuticals and Domain Associates. Novacea operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
- Headquarter Richmond, United States
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$35 M (USD)
in 1 rounds
-
Latest Funding Round
$35 M (USD), Series C
Jan 08, 2004
-
Investors
Apax Partners
& 6 more
-
Employee Count
Not available
-
Acquired by
Transcept Pharmaceuticals
(Sep 02, 2008)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Novacea
Novacea has successfully raised a total of $35M through 1 strategic funding round. The most recent funding activity was a Series C round of $35 million completed in January 2004. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Novacea
Novacea has secured backing from 7 investors, including venture fund investors. Prominent investors backing the company include Apax Partners, Transcept Pharmaceuticals and Domain Associates.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Equity investments are focused on tech, services, and consumer sectors.
|
Locked | Locked | Locked | |
|
Life science & tech focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Venture capital investments are offered to startups by NEA.
|
Locked | Locked | Locked |
Investor details for Novacea
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Novacea
Investment portfolio details for Novacea
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Novacea
Detailed financials for Novacea
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Novacea Comparisons
Peer comparison for Novacea
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Novacea
Novacea operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Revolution Medicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Cancer therapies are developed using selective pathway inhibitors.
|
|
| Locked | Locked | Locked |
Therapeutics for cancer and rare diseases are developed.
|
Detailed competitors of Novacea
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Novacea
Complete news archive for Novacea
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Novacea
Novacea was founded in 2001 and raised its 1st funding round 3 years after it was founded.
Novacea is headquartered in Richmond, United States. It is registered at Richmond, Virginia, United States.
Novacea is a funded company, having raised a total of $35M across 1 funding round to date.
Novacea Pharmaceuticals was established in 2001 in Richmond, United States, within the biotechnology sector. Focus was placed on in-licensing and advancing cancer therapies, including Asentar in phase 3 trials for androgen-independent prostate cancer and phase 2 for advanced pancreatic cancer, as well as AQ4N in phase 1b2a trials for glioblastoma multiforme. Acquisition by Transcept Pharmaceuticals occurred in September 2008, leading to a merger.
Novacea's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Novacea has 7 investors. Key investors include Apax Partners, Transcept Pharmaceuticals, Domain Associates, NEA, and Versant Ventures.